(Q35218769)

7 August 2017

1 reference

title

Memantine: update on the current evidence (English)

1 reference

7 August 2017

Hans J Möbius

1

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

International Journal of Geriatric Psychiatry

7 August 2017

published in

1 reference

7 August 2017

volume

18

1 reference

7 August 2017

issue

Suppl 1

1 reference

7 August 2017

page(s)

S47-54

1 reference

The incidence of dementia: a meta-analysis

7 August 2017

cites work

1 reference

Incidence of and risk factors for hallucinations and delusions in patients with probable AD.

21 January 2018

1 reference

Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats

21 January 2018

1 reference

7 January 2021

The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease

1 reference

7 January 2021

Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease--a unified glutamatergic hypothesis on the mechanism of action

1 reference

7 January 2021

Challenging the cholinergic hypothesis in Alzheimer disease.

1 reference

7 January 2021

Worldwide prevalence and incidence of dementia

1 reference

7 January 2021

Excitatory amino acids and Alzheimer's disease

1 reference

7 January 2021

Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy

1 reference

7 January 2021

Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy.

1 reference

7 January 2021

Glutamate toxicity in chronic neurodegenerative disease.

1 reference

7 January 2021

The question of familial meningiomas and schwannomas: NF2B or not to be?

1 reference

7 January 2021

Memantine in vascular dementia

1 reference

7 January 2021

Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).

1 reference

7 January 2021

Glutamate in CNS disorders as a target for drug development: an update

1 reference

7 January 2021

Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan).

1 reference

7 January 2021

Memantine in moderate-to-severe Alzheimer's disease

1 reference

7 January 2021

Pathological verification of ischemic score in differentiation of dementias.

1 reference

7 January 2021

Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity, and ordinality.

1 reference

7 January 2021

Triggering and execution of neuronal death in brain ischaemia: two phases of glutamate release by different mechanisms

1 reference

7 January 2021

A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).

1 reference

7 January 2021

Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease

1 reference

7 January 2021

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

1 reference

7 January 2021

Severe dementia: a common condition entailing high costs at individual and societal levels.

1 reference

7 January 2021

Infusion of (+) -MK-801 and memantine -- contrasting effects on radial maze learning in rats with entorhinal cortex lesion

1 reference

7 January 2021

Identifiers

DOI

10.1002/GPS.939

1 reference

7 August 2017

1 reference